
Friday, May 28, 2021 11:45:30 AM
Recent OCGN News
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress • GlobeNewswire Inc. • 04/29/2025 11:30:40 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/25/2025 08:59:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/25/2025 08:58:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/25/2025 08:56:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/25/2025 08:45:33 PM
- Ocugen to Present at the 2025 Cell & Gene Meeting on the Med • GlobeNewswire Inc. • 04/08/2025 12:02:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/04/2025 01:23:08 PM
- Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema • GlobeNewswire Inc. • 03/18/2025 12:02:09 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/05/2025 09:30:52 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2025 02:42:59 PM
- Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 03/05/2025 12:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2025 11:59:40 AM
- Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease • GlobeNewswire Inc. • 03/03/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2025 01:43:25 PM
- Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease • GlobeNewswire Inc. • 02/27/2025 01:46:50 PM
- Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 02/21/2025 01:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2025 01:39:20 PM
- Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 02/12/2025 12:42:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/07/2025 09:06:13 PM
- Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa • GlobeNewswire Inc. • 02/03/2025 11:30:42 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/31/2025 09:15:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2025 02:04:19 PM
- Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 • GlobeNewswire Inc. • 01/27/2025 11:30:20 AM
7.2 MW Glor Rd Solar Project in Development by SolarBank in New York • GY2 • Apr 29, 2025 9:06 AM
Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology • AVAI • Apr 29, 2025 8:00 AM
Cannabix Enters Sales Distribution Agreement with Alco Prevention Canada for BreathLogix Autonomous Alcohol Breathalyzer • BLO • Apr 28, 2025 8:49 AM
Veri Medtech (VRHI) Retains PCAOB Auditor • VRHI • Apr 28, 2025 8:30 AM
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • COEP • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM